aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Second Genome, Inc., a US-based biotech firm, develops therapeutic products targeting infection, immunity, and metabolic diseases. The company focuses on microbiome modulators to create innovative treatments that address significant health challenges.
Second Genome has made notable strides in the biotechnology sector, contributing to advancements in microbiome research and therapeutic development. Their work has the potential to significantly impact the treatment of various diseases, enhancing patient outcomes and advancing medical science.
Operating Status
Acquired
Ownership Type(s)
Venture Capital, Equity
Main Product(s)
Therapeutic Products
Technology
Biotech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Second Genome founded?
Second Genome was founded in 2009.
Where is Second Genome's headquarters located?
Second Genome's headquarters is located in South San Francisco, CA, US.
How many employees does Second Genome have?
Second Genome has 25 employees as of Feb 5, 2024.
How much has Second Genome raised to-date?
As of July 05, 2023, Second Genome has raised a total of $62.5M (USD) since Oct 3, 2017.
Add Comparison
Total Raised to Date
$62.5M
USD
Last Update Oct 3, 2017
Total Employees Over Time
25
As of Feb 2024
Second Genome Address
341 Allerton Av
South San Francisco,
California
94080-4816
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts